Unjha Formulations Ltd - Stock Valuation and Financial Performance

BSE: 531762 | NSE: | Pharmaceuticals & Drugs | Small Cap

Unjha Formulations Share Price

24 0.79 3.40%
as on 21-Feb'25 16:59

DeciZen - make an informed investing decision on Unjha Formulations

M-Cap below 100cr DeciZen not available

Unjha Formulations stock performance -

P/E Ratio (SA):
16.85
Market Cap:
10.8 Cr.
52-wk low:
17.1
52-wk high:
39

Is Unjha Formulations Ltd an attractive stock to invest in?

1. Is Unjha Formulations Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Unjha Formulations Ltd is a good quality company.

2. Is Unjha Formulations Ltd undervalued or overvalued?

The key valuation ratios of Unjha Formulations Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Unjha Formulations Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Unjha Formulations Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Unjha Formulations:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Unjha Formulations Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 68.7%73.7%67.6%32.2%25.4%25.6%26.8%21.1%16.8%19.5%-
Value Creation
Index
3.94.33.81.30.80.80.90.50.20.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 8.910.412.211.311.410.61014.213.218.516
Sales YoY Gr.-16.1%18%-7.7%1.1%-7.2%-6%42.2%-7.1%40.7%-
Adj EPS 0.40.60.70.60.70.7-00.30.60.61.4
YoY Gr.-46.2%15.8%-10.6%13.6%1.5%-104.4%NA87.5%3.3%-
BVPS (₹) 0.40.91.62.23.44.14.34.95.56.17.9
Adj Net
Profit
0.20.30.30.30.30.300.10.30.31
Cash Flow from Ops. -0.70.40.40.1-0.10.4-0.70.3-0.31-
Debt/CF from Ops. -0.600.10000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 8.4%10.1%22.9%40.7%
Adj EPS 5.3%-1.5%NA3.3%
BVPS37.4%12.7%12.5%11.3%
Share Price 18.8% 30.3% 32.3% 8.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
57.249.537.124.42218.4-0.8711.610.720.3
Op. Profit
Mgn %
2.13.53.132.62.33.72.33.33.15.9
Net Profit
Mgn %
22.52.42.32.62.9-0.2121.54
Debt to
Equity
2.500.10000000-
Working Cap
Days
7457516563617154595245
Cash Conv.
Cycle
-65-40-29-36-26-13213231921

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 20.30%

Sales growth is growing at healthy rate in last 3 years 22.92%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 2.08%

Latest Financials - Unjha Formulations Ltd.

Standalone Consolidated
TTM EPS (₹) 1.4 -
TTM Sales (₹ Cr.) 15.9 -
BVPS (₹.) 7.9 -
Reserves (₹ Cr.) -1 -
P/BV 3.03 -
PE 16.85 -
From the Market
52 Week Low / High (₹) 17.10 / 39.00
All Time Low / High (₹) 1.00 / 39.00
Market Cap (₹ Cr.) 10.8
Equity (₹ Cr.) 4.5
Face Value (₹) 10
Industry PE 37.5

Quarterly Results

 Mar'24 YoY Gr. Rt. %Jun'24 YoY Gr. Rt. %Sep'24 YoY Gr. Rt. %Dec'24 YoY Gr. Rt. %
Sales (₹ Cr.) 32.5 73.723.4 95.523.7 68.943.1 30.9
Adj EPS (₹) 0.6 -74.50.3 -43.40.6 -40.93 -16.4
Op. Profit Mgn % 25.78 -2573 bps27.08 -1020 bps19.20 -841 bps39.68 211 bps
Net Profit Mgn % 4.72 -2291 bps3.26 -650 bps6.03 -895 bps17.76 -683 bps

Management X-Ray of Unjha Formulations:

Shareholding Pattern

JavaScript chart by amCharts 3.21.5
JavaScript chart by amCharts 3.21.5Promoters:36.92%Institutions:0%Non-Institutions:63.08%

Promoter's Holding & Share Pledging

JavaScript chart by amCharts 3.21.5Sep22Dec22Mar23Jun23Sep23Dec23Mar24Jun24Sep24Dec240%10%20%30%40%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Unjha Formulations

MRP
spaceLock icon
MOS
spaceLock icon%
DP
spaceLock icon
Base EPS
spaceLock icon
DPS
spaceLock icon
MRP: ₹ 0
DP: ₹0
Base EPS ₹:
DPS ₹:
MOS (%):
Expected EPS Growth Rate:
0%
Base 0%
50%
Expected Rate of Return:
0%
Base 0%
50%
Future PE:
0
Base 0
200
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max

Event Update

Login/Register to view analysis.

Analyst's Notes

No data found!

Key Ratios of Unjha Formulations

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Company Name CMP(₹)
Change ₹(%)
Market Cap
Net Sales (₹ Cr.)
Latest EPS (₹)
Net Profit Margin %
Latest P/E
Latest P/BV
Alembic Pharma 802.8 -10.6 (-1.3%) Small Cap 6,229 30.8 9.6 26.4 3.2
Laurus Labs 521.1 -15.4 (-2.9%) Small Cap 5,041 3.7 3.1 144.5 6.9
Piramal Pharma 208.6 -9.5 (-4.3%) Small Cap 4,390 5.2 8.4 42.1 4.1
Ajanta Pharma 2,607.3 -63.1 (-2.4%) Small Cap 4,209 71.9 19 37.2 8.5
Gland Pharma 1,524.3 3.9 (0.3%) Small Cap 4,167 68.1 24.8 22.3 2.7
Natco Pharma 797.8 4.8 (0.6%) Small Cap 3,999 104.1 34.5 7.6 2
Granules India 509 -18.4 (-3.5%) Small Cap 3,755 13.3 11.7 39.7 3.9
Emcure Pharma 996.8 5.2 (0.5%) Small Cap 3,498 8.5 4.4 116.8 6.5
JB Chem & Pharma 1,605.5 -25 (-1.5%) Small Cap 3,299 40.4 16.1 40.4 7.7
Sanofi India 5,076.8 -91.3 (-1.8%) Small Cap 2,851 184.4 20.8 28 15.5
Shows rows:

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales8.9310.3712.2411.3011.4210.609.9614.1613.1518.50
Operating Expenses 8.751011.8610.9511.1210.359.5913.8412.7217.92
Manufacturing Costs1.271.361.821.541.901.941.862.271.031.20
Material Costs6.437.679.118.517.837.366.7310.4810.4515.28
Employee Cost 0.270.260.300.350.420.440.370.460.510.59
Other Costs 0.770.710.640.560.970.610.630.630.720.85
Operating Profit 0.190.360.380.340.300.250.360.320.430.58
Operating Profit Margin (%) 2.1%3.5%3.1%3.0%2.6%2.3%3.7%2.3%3.3%3.1%
Other Income 0.090.080.110.040.100.260.220.190.030.01
Interest 0.010.100.100.020.010.120.170.130.060.05
Depreciation 0.090.080.090.100.090.080.080.080.080.08
Exceptional Items 0000000000
Profit Before Tax 0.170.260.300.260.300.310.330.300.330.45
Tax 0000000.230.050.050.17
Profit After Tax 0.170.260.300.260.300.310.100.250.280.28
PAT Margin (%) 1.9%2.5%2.4%2.3%2.6%2.9%1.0%1.8%2.1%1.5%
Adjusted EPS (₹)0.40.60.70.60.70.70.20.60.60.6
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 0.390.650.941.211.511.811.922.172.452.73
Share Capital 4.484.484.484.484.484.484.484.484.484.48
Reserves -4.09-3.83-3.54-3.27-2.97-2.67-2.56-2.31-2.03-1.75
Minority Interest0000000000
Debt0.4000.050000000
Long Term Debt000.050000000
Short Term Debt0.40000000000
Trade Payables2.512.282.792.752.101.861.601.250.942.04
Others Liabilities 00000.050.040.010.040.020.16
Total Liabilities 3.302.933.783.963.653.723.533.453.414.93

Fixed Assets

Gross Block3.673.703.984.024.064.164.234.254.354.46
Accumulated Depreciation2.582.672.762.862.943.023.103.183.263.34
Net Fixed Assets1.091.031.221.161.121.141.121.071.101.12
CWIP 0000000000
Investments 0000000000
Inventories0.730.551.161.020.550.481.151.071.141.26
Trade Receivables0.680.810.650.781.341.150.980.701.051.61
Cash Equivalents 0.200.190.340.490.650.940.170.430.010.87
Others Assets0.600.350.400.51000.110.190.120.07
Total Assets 3.302.933.783.963.653.723.533.453.414.93

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity -0.700.410.390.14-0.120.39-0.700.28-0.261.03
PBT 0.170.260.300.260.300.310.100.250.330.45
Adjustment 0.110.190.190.120.100.200.250.210.130.13
Changes in Working Capital -0.970.070-0.23-0.510.01-0.89-0.05-0.670.49
Tax Paid -0.010000000-0.05-0.05
Cash Flow From Investing Activity -0.09-0.02-0.280.060.04-0.10-0.06-0.02-0.10-0.11
Capex -0.09-0.02-0.280.060.04-0.10-0.06-0.02-0.10-0.11
Net Investments 0000000000
Others 0000000000
Cash Flow From Financing Activity 0.40-0.400.05-0.050.23000-0.06-0.05
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 000.05-0.05000000
Interest Paid 00000000-0.06-0.05
Dividend Paid 0000000000
Others 0.40-0.40000.2300000
Net Cash Flow -0.38-0.010.150.150.160.29-0.770.26-0.420.86
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)244.1889.7552.4831.1824.2218.575.5512.3512.2210.72
ROCE (%)68.6673.767.6132.1525.4125.5726.821.1316.7619.53
Asset Turnover Ratio2.533.333.652.9232.882.754.063.834.43
PAT to CFO Conversion(x)-4.121.581.30.54-0.41.26-71.12-0.933.68
Working Capital Days
Receivable Days32262223344339222426
Inventory Days29232635251830293124
Payable Days1721141011191139894503836

Unjha Formulations Ltd Stock News

Unjha Formulations Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Unjha Formulations on 21-Feb-2025 16:59 is ₹24.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Feb-2025 16:59 the market cap of Unjha Formulations stood at ₹10.75.
The latest P/E ratio of Unjha Formulations as of 21-Feb-2025 16:59 is 16.85.
The latest P/B ratio of Unjha Formulations as of 21-Feb-2025 16:59 is 3.03.
The 52-week high of Unjha Formulations is ₹39.00 and the 52-week low is ₹17.10.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Unjha Formulations is ₹15.92 ( Cr.) .

About Unjha Formulations Ltd

Unjha Formulations (U-For), incorporated in 1987, is the sister concern of Urvesh Psyllium Industries Limited. U-For is the pharmaceuticals manufacturing unit, which is going to various category of formulation like tablet, capsule, oral liquids, injectables (SVP) and powder section to manufacture ayurvedic as well as allopathy products.

Fibron Powder & Fibron Sugar Free Powder are the branded ayurvedic products of the company, based on psyllium husk. The products met with an overwhelming success in our domestic market. The products mainly caters to somewhat sophisticated market segment who is conscious about their health and at the same time are very particular about various flavour like Orange, Lemon, Lime & Mango taste of the product.

Fibron Powder & Fibron SF powder offer excellent value for the money. Speed U - for could able to promote Fibron Powder & Fibron Powder SF at a most competitive price without sacrificing on quality mainly because their sister concern unit Urvesh Psyllium Industries Ltd. is one of the largest raw material supplier and processor of plyllium in the world. It may be important to note here that even Glaxo India Ltd, Proctor & Gamble, Nicholas Piramal India Ltd are the company's most valued costumers.

The company has entered into an agreement with Nicholas Piramal India for sale of Isabgol Husk based product `Tybogel` and Morepen Laboratories for sale of Dr.Mopren Sat Isabgol.

Urvesh Psyllium Industries Limited is the leading processor and exporter of Psyllium Husk & Powder in India.The company is in this line of business since last 52 years (i.e. from 1949). Initially it processed and supplied Psyllium products in local market but, looking to the worldwide demand, in 1966 it started to export Psyllium Products in the name of Rajendra Brothers. Later on with the increase of demand from overseas buyers there rose a need to expand the business, and thus Urvesh Psyllium Industries was formed in 1985, which later on was converted into a Limited Company in the year 1995.

Product range of the company includes:

  • Fibron Powder
  • Fibron Sugar Free Powder
  • Psyllium Capsules

Achievements/ recognition:

  • GMP & ISO:9001-2000 certified unit.
Read More Read Less
You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on